AstraZeneca: Three key things to know about the embattled vaccine
Al Jazeera
The world is waiting for EU regulators to deliver a verdict on whether the vaccine is linked to rare blood clots.
AstraZeneca’s COVID-19 vaccine is back in the headlines again, with European medicines regulators poised to deliver their verdict on possible links between the shot and rare blood clots in a small number of recipients. The European Medicines Agency (EMA) is scheduled to make the announcement at a briefing scheduled to take place at 14:00 GMT on Wednesday. Several European countries have stopped using the vaccine on younger adults due to blood clotting concerns.More Related News